Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ark Biosciences
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
How Paxlovid Approval May Influence China's Pandemic Policies
In a surprise move, China has conditionally approved Pfizer’s oral COVID-19 antiviral Paxlovid, a development that may have far-reaching consequences for the country's pandemic policies and domestic drug developers.
Novartis Seeks To Block Alleged Infringer Of Votrient Patent In India
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
New Designations Set To Speed Hemlibra, CAR-T In China
China is set to grant priority reviews to major biologics from Roche, the first CAR-T therapy from Wuxi Juno, and breakthrough therapy designation to a pediatric respiratory antiviral from ArkBio.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.